Literature DB >> 26885243

The factors affecting early death after the initial therapy of acute myeloid leukemia.

Umit Yavuz Malkan1, Gursel Gunes1, Eylem Eliacik1, Ibrahim Celalettin Haznedaroglu1, Sezgin Etgul1, Tuncay Aslan1, Okan Yayar2, Seda Aydin1, Haluk Demiroglu1, Osman Ilhami Ozcebe1, Nilgun Sayinalp1, Hakan Goker1, Salih Aksu1, Yahya Buyukasik1.   

Abstract

There are some improvements in management of acute myeloid leukemia (AML). However, induction-induced deaths still remain as a major problem. The aim of this study is to assess clinical parameters affecting early death in patients with AML. 199 AML patients, who were treated with intensive, non-intensive or supportive treatment between 2002 and 2014 in Hacettepe Hematology Department, were analyzed retrospectively. In our study early death rate for elderly was found to be lower than previous reports whereas it was similar for those who were under age of 60. Better ECOG performance (ECOG performance score 0 and 1) and non-intensive treatment associated with lower early death rates, however APL-type disease associated with higher early death rates. ECOG performance score at diagnosis was found to be the most related independent factor with higher rate of early death in 15 days after treatment (P<0.001). Therefore we decided to understand the factors which were related with ECOG. WBC count at diagnosis was found to be the only related parameter with ECOG performance score. Leucocyte count at diagnosis appears like to have an indirect effect on early death in AML patients. It maybe suggested that in recent years there is an improvement in early death rates of elderly AML patients. The currently reported findings require prospective validation and would encourage the incorporation of other next generation genomics for the prediction of early death and overall risk status of AML.

Entities:  

Keywords:  Acute myeloid leukemia; early death

Year:  2015        PMID: 26885243      PMCID: PMC4730029     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  18 in total

1.  Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia.

Authors:  Irena Djunic; Marijana Virijevic; Aleksandra Novkovic; Vladislava Djurasinovic; Natasa Colovic; Ana Vidovic; Nada Suvajdzic-Vukovic; Dragica Tomin
Journal:  Hematology       Date:  2012-03       Impact factor: 2.269

2.  Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.

Authors:  Hagop Kantarjian; Susan O'brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey
Journal:  Cancer       Date:  2006-03-01       Impact factor: 6.860

3.  Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapy.

Authors:  T Naoe; Y Tagawa; H Kiyoi; Y Kodera; S Miyawaki; N Asou; K Kuriyama; S Kusumoto; C Shimazaki; K Saito; H Akiyama; T Motoji; M Nishimura; K Shinagawa; R Ueda; H Saito; R Ohno
Journal:  Leukemia       Date:  2002-02       Impact factor: 11.528

4.  Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment.

Authors:  Roland B Walter; Megan Othus; Gautam Borthakur; Farhad Ravandi; Jorge E Cortes; Sherry A Pierce; Frederick R Appelbaum; Hagop A Kantarjian; Elihu H Estey
Journal:  J Clin Oncol       Date:  2011-10-03       Impact factor: 44.544

5.  Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.

Authors:  Utz Krug; Christoph Röllig; Anja Koschmieder; Achim Heinecke; Maria Cristina Sauerland; Markus Schaich; Christian Thiede; Michael Kramer; Jan Braess; Karsten Spiekermann; Torsten Haferlach; Claudia Haferlach; Steffen Koschmieder; Christian Rohde; Hubert Serve; Bernhard Wörmann; Wolfgang Hiddemann; Gerhard Ehninger; Wolfgang E Berdel; Thomas Büchner; Carsten Müller-Tidow
Journal:  Lancet       Date:  2010-12-03       Impact factor: 79.321

6.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

7.  Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia.

Authors:  Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Elias Jabbour; William Wierda; Tapan Kadia; Sherry Pierce; Jianqin Shan; Michael Keating; Emil J Freireich
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

8.  Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.

Authors:  Keith Wheatley; Cassandra L Brookes; Andrew J Howman; Anthony H Goldstone; Donald W Milligan; Archibald G Prentice; Anthony V Moorman; Alan K Burnett
Journal:  Br J Haematol       Date:  2009-03-26       Impact factor: 6.998

9.  Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.

Authors:  Jean-Valère Malfuson; Anne Etienne; Pascal Turlure; Thierry de Revel; Xavier Thomas; Nathalie Contentin; Christine Terré; Sophie Rigaudeau; Dominique Bordessoule; Norbert Vey; Claude Gardin; Hervé Dombret
Journal:  Haematologica       Date:  2008-10-06       Impact factor: 9.941

10.  Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.

Authors:  R J Mayer; R B Davis; C A Schiffer; D T Berg; B L Powell; P Schulman; G A Omura; J O Moore; O R McIntyre; E Frei
Journal:  N Engl J Med       Date:  1994-10-06       Impact factor: 91.245

View more
  3 in total

1.  Clinical Profile and Short Term Outcome of Adult Patients with Acute Myeloid Leukemia.

Authors:  Sherin Jacob; Sajini Elizabeth Jacob; Bettadpura Shamanna Suryanarayana; Tarun Kumar Dutta
Journal:  Indian J Hematol Blood Transfus       Date:  2018-11-26       Impact factor: 0.900

2.  Acute Myelogenous Leukemia with the t(7;7)(p15;p22) Translocation, a Novel Simple Variant of t(7;11)(p15;p15) Translocation: First Description.

Authors:  Motoharu Shibusawa
Journal:  Case Rep Hematol       Date:  2021-04-19

3.  Leukapheresis Does Not Improve Early Survival Outcome of Acute Myeloid Leukemia with Leukostasis Patients - A Dual-Center Retrospective Cohort Study.

Authors:  Ikhwan Rinaldi; Resti Mulya Sari; Vanya Utami Tedhy; Kevin Winston
Journal:  J Blood Med       Date:  2021-07-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.